Natural Products and their (Semi-)Synthetic Forms in the Treatment of Migraine: History and Current Status

被引:13
作者
Tauchen, Jan [1 ]
机构
[1] Czech Univ Life Sci Prague, Fac Agrobiol Food & Nat Resources, Dept Food Sci, Kamycka 129, Prague 16500, Czech Republic
关键词
Headache; migraine disorders natural compounds; nociception; novel targets; pain; therapy; ST-JOHNS-WORT; ACETYLSALICYLIC-ACID; BOTULINUM TOXIN; ANIMAL-MODEL; HEADACHE; PARTHENOLIDE; MANAGEMENT; MEDICINE; CANNABIS; PAIN;
D O I
10.2174/0929867326666190125155947
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Migraine may be described as a headache with moderate to extreme pain that is often accompanied by incapacitating neurological symptoms. It is estimated that 12% of the world population suffers from migraine. Although a number of drugs have been used for treatment of migraine, most of these are not effective for every patient and may have undesirable side-effects. Thus, there is an enormous unmet need in current migraine therapy for discovering safer and more effective agents. Methods: The information summarized in this review was obtained through extensive literature review and search of relevant books and articles with the use of Web of Knowledge and SciVerse Scopus databases. Results: Greater understanding of the molecular mechanisms underlying the etiopathogenesis of migraine is helpful in identifying novel targets for antimigraine drugs such as cannabinoid, histamine, and melatonin receptors. In the past, natural product-derived constituents have served as an invaluable source of numerous medicinally useful antimigraine agents and it may be expected that further promising drug candidates from natural products will be discovered for antimigraine pharmacotherapy with better efficacy and fewer adverse-effects. Conclusion: The discovery of novel targets in migraine therapy has opened new horizons for compounds that have not been clinically tested or that previously failed in clinical trials as potential antimigraine drugs. Ginkgolide B, melatonin, histamine, oxytocin, various ribosomal peptide toxins, kavalactones, devil's claw-derived compounds, salvinorin A and petasin are among those agents that show considerable promise as novel drugs in migraine prevention and treatment. It is necessary to conduct more research to better understand their antimigraine action, to confirm their effectiveness and safety, and to introduce them into clinical practice.
引用
收藏
页码:3784 / 3808
页数:25
相关论文
共 93 条
[1]   Psychoactive substances as a last resort-a qualitative study of self-treatment of migraine and cluster headaches [J].
Andersson, Martin ;
Persson, Mari ;
Kjellgren, Anette .
HARM REDUCTION JOURNAL, 2017, 14
[2]  
[Anonymous], 2013, WORK LIST ALL PLANT
[3]   PARTIAL AGONIST PROPERTIES OF RAUWOLSCINE AND YOHIMBINE FOR THE INHIBITION OF ADENYLYL-CYCLASE BY RECOMBINANT HUMAN 5-HT(1A)-RECEPTORS [J].
ARTHUR, JM ;
CASANAS, SJ ;
RAYMOND, JR .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (11) :2337-2341
[4]   Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective Agonists [J].
Ashton, John C. ;
Wright, Jason L. ;
McPartland, John M. ;
Tyndall, Joel D. A. .
CURRENT MEDICINAL CHEMISTRY, 2008, 15 (14) :1428-1443
[5]  
Barceloux DG., 2008, MED TOXICOLOGY NATUR
[6]   Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science [J].
Baron, Eric P. .
HEADACHE, 2018, 58 (07) :1139-1186
[7]   Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ... [J].
Baron, Eric P. .
HEADACHE, 2015, 55 (06) :885-916
[8]   The Use and Method of Action of Intravenous Lidocaine and Its Metabolite in Headache Disorders [J].
Berk, Thomas ;
Silberstein, Stephen D. .
HEADACHE, 2018, 58 (05) :783-789
[9]  
Bischoff K, 2018, VETERINARY TOXICOLOGY: BASIC AND CLINICAL PRINCIPLES, 3RD EDITION, P385, DOI 10.1016/B978-0-12-811410-0.00022-2
[10]  
Bolcskei Hedvig, 2009, Recent Pat CNS Drug Discov, V4, P14